Cargando…
T Cell Dysfunction in Cancer Immunity and Immunotherapy
In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659036/ https://www.ncbi.nlm.nih.gov/pubmed/31379886 http://dx.doi.org/10.3389/fimmu.2019.01719 |
_version_ | 1783439056480239616 |
---|---|
author | Xia, Anliang Zhang, Yan Xu, Jiang Yin, Tailang Lu, Xiao-Jie |
author_facet | Xia, Anliang Zhang, Yan Xu, Jiang Yin, Tailang Lu, Xiao-Jie |
author_sort | Xia, Anliang |
collection | PubMed |
description | In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy. |
format | Online Article Text |
id | pubmed-6659036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66590362019-08-02 T Cell Dysfunction in Cancer Immunity and Immunotherapy Xia, Anliang Zhang, Yan Xu, Jiang Yin, Tailang Lu, Xiao-Jie Front Immunol Immunology In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy. Frontiers Media S.A. 2019-07-19 /pmc/articles/PMC6659036/ /pubmed/31379886 http://dx.doi.org/10.3389/fimmu.2019.01719 Text en Copyright © 2019 Xia, Zhang, Xu, Yin and Lu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xia, Anliang Zhang, Yan Xu, Jiang Yin, Tailang Lu, Xiao-Jie T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title_full | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title_fullStr | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title_full_unstemmed | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title_short | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
title_sort | t cell dysfunction in cancer immunity and immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659036/ https://www.ncbi.nlm.nih.gov/pubmed/31379886 http://dx.doi.org/10.3389/fimmu.2019.01719 |
work_keys_str_mv | AT xiaanliang tcelldysfunctionincancerimmunityandimmunotherapy AT zhangyan tcelldysfunctionincancerimmunityandimmunotherapy AT xujiang tcelldysfunctionincancerimmunityandimmunotherapy AT yintailang tcelldysfunctionincancerimmunityandimmunotherapy AT luxiaojie tcelldysfunctionincancerimmunityandimmunotherapy |